Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus

A Study of LY3209590 in Japanese Participants With Type 2 Diabetes

NCT03603704 ·Status: COMPLETED ·Phase: PHASE1

Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 Diabetes

NCT01615978 ·Status: COMPLETED ·Phase: PHASE1

A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus

NCT05596747 ·Status: COMPLETED ·Phase: PHASE1

A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus

NCT05086445 ·Status: COMPLETED ·Phase: PHASE1

A Study of LY3537021 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

NCT04586907 ·Status: COMPLETED ·Phase: PHASE1

A Study of Multiple Doses of LY3305677 in Healthy Participants

NCT03325387 ·Status: COMPLETED ·Phase: PHASE1

Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study

NCT01194830 ·Status: COMPLETED ·Phase: PHASE3

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

NCT00333151 ·Status: COMPLETED ·Phase: PHASE3

Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With Prediabetes

NCT04131582 ·Status: UNKNOWN ·Phase: PHASE3

A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes

NCT03315780 ·Status: COMPLETED ·Phase: PHASE4

Clinical Study on the Improvement of Diabetic Neuropathic Pain by Liraglutide

NCT04137328 ·Status: UNKNOWN ·Phase: NA

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

NCT01183013 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus

NCT02589639 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes

NCT05834868 ·Status: COMPLETED ·Phase: PHASE3

Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients

NCT00935220 ·Status: COMPLETED ·Phase: PHASE1

Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control

NCT00621140 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)

NCT00577824 ·Status: COMPLETED ·Phase: PHASE3

Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes

NCT01940965 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

NCT01646320 ·Status: COMPLETED ·Phase: PHASE3

A Study of LY2189265 in Japanese Patients With Type 2 Diabetes

NCT01001104 ·Status: COMPLETED ·Phase: PHASE2

Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes

NCT00154414 ·Status: COMPLETED ·Phase: PHASE2

A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes

NCT00382239 ·Status: COMPLETED ·Phase: PHASE2

Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes

NCT01403025 ·Status: COMPLETED

Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control

NCT07244003 ·Status: RECRUITING ·Phase: PHASE4

Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin

NCT07057479 ·Status: WITHDRAWN ·Phase: PHASE3